Package Leaflet: Information for the Patient
Onglyza 2.5mg film-coated tablets
saxagliptin
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Onglyza contains the active substance saxagliptin which belongs to a group of medicines called “oral anti-diabetics”. They help to control the level of sugar in your blood.
Onglyza is used to treat adult patients aged 18 years or older with “type 2 diabetes”, if the disease cannot be controlled adequately with a single oral anti-diabetic medicine, diet, and exercise. Onglyza is used alone or in combination with insulin or other anti-diabetic medicines.
It is important that you follow the advice about diet and exercise given by your doctor or healthcare professional.
Do not take Onglyza
Warnings and precautions
Consult your doctor or pharmacist before starting to take Onglyza:
Diabetic skin lesions are a common complication of diabetes. Skin rash has been observed with Onglyza (see section 4) and with certain anti-diabetic medicines in the same class as Onglyza. You are advised to follow the skin and foot care recommendations given by your doctor or healthcare professional. Contact your doctor if you find blisters on your skin, as it may be a sign of a disease called bullous pemphigoid. Your doctor may ask you to stop taking Onglyza.
Children and adolescents
Onglyza is not recommended for children and adolescents under 18 years of age.
Other medicines and Onglyza
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
In particular, you should tell your doctor if you are using medicines that contain any of the following active substances:
Pregnancy and breast-feeding
Consult your doctor before taking Onglyza if you are pregnant or planning to become pregnant. You must not use Onglyza if you are pregnant.
Consult your doctor if you want to breast-feed while taking this medicine. It is not known if Onglyza passes into human breast milk. You must not take this medicine if you are breast-feeding or planning to breast-feed.
Driving and using machines
If you feel dizzy while taking Onglyza, do not drive or use tools or machines. Hypoglycaemia can affect your ability to drive or use machines or work with a firm support and there is a risk of hypoglycaemia when taking this medicine in combination with medicines with a known effect of hypoglycaemia, such as insulin or sulphonylureas.
Onglyza contains lactose
The tablets contain lactose (milk sugar). If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
Onglyza contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose; this is essentially “sodium-free”.
Follow exactly the instructions of administration of this medicine given by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is 5 mg once a day.
If you have reduced kidney function, your doctor may prescribe a lower dose. This is a 2.5 mg tablet once a day.
Your doctor may prescribe Onglyza alone or in combination with insulin or other anti-diabetic medicines. If so, remember to take these other medicines as directed by your doctor to achieve the best results for your health.
How to take Onglyza
The tablets must not be divided or crushed. Swallow the whole tablet with a little water. You can take the tablet with or without food. The tablet can be taken at any time of the day, however, try to take the tablet at the same time each day. This will help you remember to take it.
If you take more Onglyza than you should
If you take more tablets than you should, consult a doctor immediately.
If you forget to take Onglyza
If you stop taking Onglyza
Continue to take Onglyza until your doctor tells you to stop. This is to help you keep your blood sugar levels under control.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some symptoms need immediate medical attention:
You should stop taking Onglyza and contact your doctor immediately if you experience the following symptoms of low blood sugar: shaking, sweating, anxiety, blurred vision, tingling of the lips, paleness, mood changes, disorientation, or confusion (hypoglycaemia); very common (may affect more than 1 in 10 patients).
The symptoms of a severe allergic reaction (rare, may affect up to 1 in 1,000 patients) can include:
If you experience any of these symptoms, stop taking Onglyza and contact your doctor or nurse immediately. Your doctor may prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes.
You should stop taking Onglyza and contact your doctor immediately if you notice any of the following serious side effects:
You should contact your doctor if you experience the following side effect:
Some patients have experienced the following side effects while taking Onglyza and metformin:
Some patients have experienced the following side effects while taking Onglyza and a sulphonylurea:
Some patients have experienced the following side effects while taking Onglyza and a thiazolidinedione:
Some patients have experienced the following side effects while taking Onglyza and metformin and a sulphonylurea:
Some patients have experienced the following additional side effects while taking Onglyza alone:
Some patients have experienced the following side effects while taking Onglyza alone or in combination:
Some patients have experienced a small reduction in the number of a type of white blood cell (lymphocytes) detected by blood analysis while taking Onglyza alone or in combination.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and carton after EXP/CAD. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Do not use this medicine if the packaging is damaged or shows signs of tampering.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
What Onglyza contains
Appearance and packaging
Not all pack sizes may be marketed in your country.
Marketing authorisation holder
AstraZeneca AB
SE-151 85 Södertälje
Sweden
Manufacturer
AstraZeneca AB
Gärtunavägen
SE‑152 57 Södertälje
Sweden
AstraZeneca UK Limited
Silk Road Business Park
Macclesfield
Cheshire
SK10 2NA
United Kingdom
You can get more information about this medicine by contacting the representative of the marketing authorisation holder in your country:
Belgium/België/Belgique AstraZeneca S.A./N.V. Tel: +32 2 370 48 11 | Lithuania UAB AstraZeneca Lietuva Tel: +370 5 2660550 |
Luxembourg/Luxemburg AstraZeneca S.A./N.V. Tél/Tel: +32 2 370 48 11 | |
Czech Republic AstraZeneca Czech Republic s.r.o. Tel: +420 222 807 111 | Hungary AstraZeneca Kft. Tel.: +36 1 883 6500 |
Denmark AstraZeneca A/S Tlf: +45 43 66 64 62 | Malta Associated Drug Co. Ltd Tel: +356 2277 8000 |
Germany AstraZeneca GmbH Tel: +49 40 809034100 | Netherlands AstraZeneca BV Tel: +31 85 808 9900 |
Estonia AstraZeneca Tel: +372 6549 600 | Norway AstraZeneca AS Tlf: +47 21 00 64 00 |
Greece AstraZeneca A.E. Τηλ: +30 2 106871500 | Austria AstraZeneca Österreich GmbH Tel: +43 1 711 31 0 |
Spain AstraZeneca Farmacéutica Spain, S.A. Tel: +34 91 301 91 00 | Poland AstraZeneca Pharma Poland Sp. z o.o. Tel.: +48 22 245 73 00 |
France AstraZeneca Tél: +33 1 41 29 40 00 | Portugal AstraZeneca Produtos Farmacêuticos, Lda. Tel: +351 21 434 61 00 |
Croatia AstraZeneca d.o.o. Tel: +385 1 4628 000 | Romania AstraZeneca Pharma SRL Tel: +40 21 317 60 41 |
Ireland AstraZeneca Pharmaceuticals (Ireland) DAC Tel: +353 1609 7100 | Slovenia AstraZeneca UK Limited Tel: +386 1 51 35 600 |
Iceland Vistor hf. Sími: +354 535 7000 | Slovakia AstraZeneca AB, o.z. Tel: +421 2 5737 7777 |
Italy AstraZeneca S.p.A. Tel: +39 02 00704500 | Finland AstraZeneca Oy Puh/Tel: +358 10 23 010 |
Cyprus Αλκτωρ Φαρµακευτικ? Λτδ Τηλ: +357 22490305 | Sweden AstraZeneca AB Tel: +46 8 553 26 000 |
Latvia SIA AstraZeneca Latvija Tel: +371 67377100 | United Kingdom (Northern Ireland) AstraZeneca UK Ltd Tel: +44 1582 836 836 |
Date of last revision of this leaflet:
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
The average price of ONGLYZA 2.5 mg FILM-COATED TABLETS in October, 2025 is around 27.97 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.